Business Description
Biocon Ltd
ISIN : INE376G01013
Share Class Description:
NSE:BIOCON: Ordinary SharesTotal Employee Number:
16,561Compare
Compare
Traded in other countries / regions
532523.India Index Membership
NIFTY 500 IPO Date
2004-04-07Description
Biocon Ltd is a biopharmaceutical company engaged in the manufacture of biotechnology products, active pharmaceutical ingredients, and formulations, including biosimilar drugs for diabetes, oncology, autoimmune diseases, and ophthalmology, as well as research services. The Company focuses on the core therapeutic areas of diabetes, oncology and immunology. Its segments are Generics, Biosimilars, and CRDMO, with Biosimilars generating the maximum revenue. The Company also complies with Extended Producer Responsibility (EPR) obligations by integrating EPR considerations into packaging design, procurement practices, and vendor engagement processes. The Company generates a majority of its revenue from customers located in India, and the rest from Brazil, Singapore, and the rest of the world.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.26 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.45 | |||||
Debt-to-EBITDA | 4.55 | |||||
Interest Coverage | 1.5 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 2.27 | |||||
Beneish M-Score | -2.46 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 10.3 | |||||
3-Year EBITDA Growth Rate | 6.6 | |||||
3-Year EPS without NRI Growth Rate | -0.9 | |||||
3-Year FCF Growth Rate | -17.1 | |||||
3-Year Book Growth Rate | 12 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 30.76 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 13.81 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.24 | |||||
9-Day RSI | 44.53 | |||||
14-Day RSI | 49.25 | |||||
3-1 Month Momentum % | 16.31 | |||||
6-1 Month Momentum % | 14.04 | |||||
12-1 Month Momentum % | 6.87 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.22 | |||||
Quick Ratio | 0.79 | |||||
Cash Ratio | 0.29 | |||||
Days Inventory | 359.05 | |||||
Days Sales Outstanding | 122.85 | |||||
Days Payable | 433.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.12 | |||||
Dividend Payout Ratio | 0.1 | |||||
Forward Dividend Yield % | 0.12 | |||||
5-Year Yield-on-Cost % | 0.12 | |||||
3-Year Average Share Buyback Ratio | -10.7 | |||||
Shareholder Yield % | -9.82 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 66.19 | |||||
Operating Margin % | 8.8 | |||||
Net Margin % | 2.29 | |||||
EBITDA Margin % | 20.17 | |||||
FCF Margin % | 0.49 | |||||
OCF Margin % | 11.85 | |||||
ROE % | 1.4 | |||||
ROA % | 0.62 | |||||
ROIC % | 2.38 | |||||
3-Year ROIIC % | 2.97 | |||||
ROC (Joel Greenblatt) % | 8.74 | |||||
ROCE % | 3.07 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 155.78 | |||||
Forward PE Ratio | 55.29 | |||||
PE Ratio without NRI | 87.82 | |||||
Shiller PE Ratio | 60.68 | |||||
Price-to-Owner-Earnings | 3188.97 | |||||
PEG Ratio | 5.17 | |||||
PS Ratio | 3.47 | |||||
PB Ratio | 2.04 | |||||
Price-to-Tangible-Book | 13.2 | |||||
Price-to-Free-Cash-Flow | 717.98 | |||||
Price-to-Operating-Cash-Flow | 29.62 | |||||
EV-to-EBIT | 57.9 | |||||
EV-to-EBITDA | 24.53 | |||||
EV-to-Revenue | 4.95 | |||||
EV-to-FCF | 1027.95 | |||||
Price-to-GF-Value | 1.25 | |||||
Price-to-Projected-FCF | 1.98 | |||||
Price-to-DCF (Earnings Based) | 9.33 | |||||
Price-to-DCF (FCF Based) | 76.29 | |||||
Price-to-Median-PS-Value | 0.66 | |||||
Price-to-Peter-Lynch-Fair-Value | 4.01 | |||||
Price-to-Graham-Number | 7.13 | |||||
Earnings Yield (Greenblatt) % | 1.72 | |||||
FCF Yield % | 0.12 | |||||
Forward Rate of Return (Yacktman) % | 17.46 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biocon Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 168,299 | ||
| EPS (TTM) (₹) | 2.77 | ||
| Beta | 1.0152 | ||
| 3-Year Sharpe Ratio | 0.43 | ||
| 3-Year Sortino Ratio | 0.64 | ||
| Volatility % | 28.91 | ||
| 14-Day RSI | 49.25 | ||
| 14-Day ATR (₹) | 10.679878 | ||
| 20-Day SMA (₹) | 427.275 | ||
| 12-1 Month Momentum % | 6.87 | ||
| 52-Week Range (₹) | 331 - 447.15 | ||
| Shares Outstanding (Mil) | 1,628.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biocon Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biocon Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2026-11-12 09:00 | In 103 days | ||
| Second quarter earnings results for 2027 | 2026-11-12 | In 102 days | ||
| General meeting for 2026 | 2026-08-06 15:30 | In 5 days | ||
| First quarter earnings conference call for 2027 | 2026-08-06 10:00 | In 5 days | ||
| First quarter earnings results for 2027 | 2026-08-05 | In 3 days | ||
| Annual report for 2026 | 2026-07-15 | 437.30 (+2.33%) | ||
| INR 0.500000 Cash Dividend | 2026-07-03 | 418.60 (-0.45%) | ||
| Fourth quarter earnings conference call for 2026 | 2026-05-08 09:00 | 382.25 (-0.46%) | ||
| Fourth quarter earnings results for 2026 | 2026-05-08 | 382.25 (-0.46%) | ||
| Third quarter earnings conference call for 2026 | 2026-02-13 09:00 | 375.05 (-0.57%) |
Show
Entries
Biocon Ltd Frequently Asked Questions
What is Biocon Ltd(NSE:BIOCON)'s stock price today?
The current price of NSE:BIOCON is ₹425.70. The 52 week high of NSE:BIOCON is ₹447.15 and 52 week low is ₹331.00.
When is next earnings date of Biocon Ltd(NSE:BIOCON)?
The next earnings date of Biocon Ltd(NSE:BIOCON) is 2026-08-05.
Does Biocon Ltd(NSE:BIOCON) pay dividends? If so, how much?
The Dividend Yield %  of Biocon Ltd(NSE:BIOCON) is 0.12% (As of Today), Highest Dividend Payout Ratio of Biocon Ltd(NSE:BIOCON) was 1.28. The lowest was 0.08. And the median was 0.11. The  Forward Dividend Yield % of Biocon Ltd(NSE:BIOCON) is 0.12%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Biocon Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers